All In Biotech

Drug Trial Radar · NCT04969315

TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma

A Phase 1/1b, Open-Label, First-in-Human Multicenter Study to Assess the Safety, Tolerability, Preliminary Efficacy, Pharmacokinetics, and Pharmacodynamics of Oral TT-10 (an Adenosine 2A Receptor Antagonist), and TT-4 Diacid (an Adenosine 2B Receptor Antagonist), as Single Agents and in Combination in Participants With Advanced Selected Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

35

Planned (sponsor's estimate)

Start

Jun 23, 2023

Primary completion

Dec 1, 2028

Study completion Mar 1, 2029

Sponsor

Lead sponsor
Portage BiotechIndustry
Sponsor type
Industry
First posted
Jul 20, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate TT-10, TT-4 and TT-10 + TT-4, (Dual Blockade) in participants with advanced selected solid tumors, who have failed or are not eligible for standard of care. The main questions it aims to answer are: 1. To evaluate the safety and tolerability of TT-10, TT-4 Diacid, and combination therapy (TT-10 + TT-4 Diacid). 2. To determine the maximum tolerated dose (MTD) or phase 2 recommended dose of TT-10, TT-4 Diacid, and combination therapy (TT-10 + TT-4 Diacid). 3. To evaluate safety of combination therapy (TT-10 + TT-4 Diacid).

Conditions

  • Renal Cell Cancer
  • Castrate Resistant Prostate Cancer
  • Non Small Cell Lung Cancer
  • Pleural Mesothelioma Malignant

Interventions

  • TT-10Drug

    TT-10 orally administered BID

  • TT-4Drug

    TT-4 is orally administered QD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of subjects with Dose Limiting Toxicities (DLTs) of TT-10, TT-4 and TT-10 + TT-4 during the dose escalation phaseTime frame: 28 Days
  2. Define the maximum tolerated dose (MTD) or phase 2 recommended dose of TT-10, TT-4 and TT-10 + TT-4 during the dose escalation phaseTime frame: Through study completion, an average of 1 year
  3. Expansion cohort primary objective - safetyTime frame: Through study completion, an average of 1 year

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.